Coronary disease & ACSRandomised controlled trial
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial
- Randomised controlled trial
- cross-over
- phenotype-blinded
- per protocol analysis
4 weeks amlodipine or ranolazine, 1-week washout, cross-over to the other drug for 4 weeks
Authors' conclusion
Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy.
Study context
- Population
- Patients with angina with nonobstructive coronary arteries undergoing blinded invasive coronary flow reserve (CFR) measurement
- Participants
- 87 patients
- Comparison
- Response to anti-ischaemic therapy in CMD vs reference
- CMDn = 57
- Referencen = 30reference
- Primary endpoint
- Change in treadmill exercise time
Primary result
As reported in the abstract
CMD vs ReferenceDifference in delta, s (95% CI)P value
amlodipine
82(37–126)
P < 0.001ranolazine
68(21–115)
P = 0.005Secondary outcomes
| Outcome | difference in delta (points) (95% CI) | P value | |
|---|---|---|---|
| Change in Seattle Angina Questionnaire summary score — CMD vs Reference · ranolazine | 7 (0–15) | P = 0.048 | |
| Change in Seattle Angina Questionnaire summary score — CMD vs Reference · amlodipine | 2 (−5 to 8) | P = 0.549 | |
| −1001020Difference, points (linear scale) |
Original publication
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial. Circulation. Published 31 October 2023. doi:10.1161/circulationaha.123.066680
Summarised from the published abstract; every number is checked against it